Press release
Personal Care
March 28, 2017

TEGO® Pep 4-Comfort, a new cosmetic active ingredient from Evonik, offers relief to sensitive skin

Essen, Germany. Evonik presents its new TEGO® Pep 4-Comfort cosmetic active ingredient at this year’s in-cosmetics tradeshow in London. This tetrapeptide selectively relieves typical symptoms of sensitive skin, visibly calming and revitalizing the skin. Scientific studies, expert assessments, and user reports have verified the efficacy of TEGO® Pep 4-Comfort.

The tetrapeptide alleviates skin irritations, such as those that typically arise from shaving. According to one study, redness and itching were reduced by 70 percent and burning by 56 percent. The active ingredient also counteracts overreactions triggered by repeated contact or external irritants such as heat.

“There are numerous mechanisms that can favor the development of sensitive skin, so we aimed for the broadest possible active profile when we developed TEGO® Pep 4-Comfort,” says Tammo Boinowitz, the head of Evonik’s Personal Care Business Line. As a result, the tetrapeptide is suitable for an extremely wide variety of applications, such as aftershaves, creams and lotions, sunscreen products, after-sun products, and cosmetic products for daily care regimens, particularly for sensitive skin. TEGO® Pep 4-Comfort from Evonik is a ready-to-use solution in water and glycerin, and can be used in all common formulations.

Sensitive skin is a problem for over half of the world’s population. The mechanisms underlying hypersensitivity have not yet been clarified in detail. The number of people affected has risen steadily over the past several years, however. Thanks to the scientifically verified effect of TEGO® Pep 4-Comfort, cosmetics manufacturers can now develop products that help optimize care for sensitive skin and alleviate skin irritations.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12,7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around
€4.3 billion in 2016.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.